Fibroblast growth factor receptor signaling as therapeutic targets in gastric cancer

doi:10.3748/wjg.v22.i8.2415

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 22, Issue 8

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (17085)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-2) series.

Item

Count

PDF

1126

WORD

403

HTML

9252

Figures (1-2)

924

Tables (1-2)

499

Sum=12204

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

587

Download

1133

Sum=1720

Publishing Process of This Article

Item

Count

Browse

1210

Download

1955

Sum=3165

Feb 28, 2016 (publication date) through Mar 18, 2026

Times Cited of This Article

Times Cited (33)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Topic Highlight

World J Gastroenterol. Feb 28, 2016; 22(8): 2415-2423
Published online Feb 28, 2016. doi: 10.3748/wjg.v22.i8.2415

Fibroblast growth factor receptor signaling as therapeutic targets in gastric cancer

Masakazu Yashiro, Tasuku Matsuoka

Masakazu Yashiro, Tasuku Matsuoka, Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan

Masakazu Yashiro, Oncology Institute of Geriatrics and Medical Science, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan

Author contributions: Yashiro M and Matsuoka T designed this review; Yashiro M wrote and edited the manuscript.

Supported by KAKENHI (partially, Grant-in-Aid for Scientific Research, No. 23390329).

Conflict-of-interest statement: There are not any financial or other interests with regard to the submitted manuscript that might be construed as a conflict of interest.

Correspondence to: Masakazu Yashiro, MD, Department of Surgical Oncology, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan. m9312510@med.osaka-cu.ac.jp

Telephone: +81-6-66453838 Fax: +81-6-66466450

Received: April 27, 2015
Peer-review started: May 1, 2015
First decision: May 18, 2015
Revised: May 25, 2015
Accepted: December 8, 2015
Article in press: December 8, 2015
Published online: February 28, 2016
Processing time: 304 Days and 0.5 Hours

Abstract

Fibroblast growth factor receptors (FGFRs) regulate a variety of cellular functions, from embryogenesis to adult tissue homeostasis. FGFR signaling also plays significant roles in the proliferation, invasion, and survival of several types of tumor cells. FGFR-induced alterations, including gene amplification, chromosomal translocation, and mutations, have been shown to be associated with the tumor initiation and progression of gastric cancer, especially in diffuse-type cancers. Therefore, the FGFR signaling pathway might be one of the therapeutic targets in gastric cancer. This review aims to provide an overview of the role of FGFR signaling in tumorigenesis, tumor progression, proliferation, and chemoresistance. We also discuss the accumulating evidence that demonstrates the effectiveness of using clinical therapeutic agents to inhibit FGFR signaling for the treatment of gastric cancer.

Keywords: Fibroblast growth factor receptor; Gastric cancer; Signaling pathway; Targeted therapy

Core tip: Fibroblast growth factor receptor (FGFR) is one of the drivers signaling in the development of gastric cancer. The use of molecular agents as targets of the FGFRs pathway has currently been approved in experimental and clinical trials as a mono-targeted approach or in combination with chemotherapeutic agents. FGFRs might be a promising therapeutic target for the treatment of gastric cancer.